FDA reviewer guidance spells out "major and minor" PMA (premarket approval) faults
This article was originally published in Clinica
The FDA has updated the guidance it uses to help staff decide whether a premarket approval application should be accepted for review. When PMAs are submitted to the agency, they are not automatically filed with the agency and assigned to a reviewer. The agency must first determine whether the application is ready for review, a process that can take up to 30 days.
You may also be interested in...
The maker of prestige-inspired cosmetics at value prices follows its TikTok viral success by teaming with Kathleen Belsten, aka Loserfruit, the second most-followed female gamer on the Amazon-owned livestreaming platform Twitch.
As distribution of Regeneron’s monoclonal antibody treatment for coronavirus begins, OWS officials worry about provider confusion with Lilly’s product due to differences in preparation and administration.
Join us for a brief audio tour around the past week's key developments in the global biopharma industry, in this podcast version of Scrip's Five Must-Know Things.